Overview
Autosomal dominant focal dystonia, DYT25 type (also called GNAL-related dystonia or DYT-GNAL) is a rare movement disorder caused by changes in the GNAL gene. Dystonia means that muscles contract involuntarily, causing twisting or repetitive movements and abnormal postures that a person cannot control. In DYT25, the dystonia typically starts in one part of the body — most often the neck (called cervical dystonia or torticollis), the face, or the vocal cords (laryngeal dystonia). Over time, it may spread to involve nearby body regions, but it usually does not become generalized to the whole body. Symptoms most commonly begin in adulthood, often between the ages of 20 and 40, though onset can vary. The neck is the most frequently affected area, leading to abnormal head positions, pain, and stiffness. When the voice box is involved, speech may become strained or breathy. Some people also develop writer's cramp or other task-specific hand dystonia. There is currently no cure for DYT25. Treatment focuses on managing symptoms. Botulinum toxin (Botox) injections into the affected muscles are the most effective and widely used therapy. Oral medications such as anticholinergics (like trihexyphenidyl), muscle relaxants, and benzodiazepines may also help. In more severe or medication-resistant cases, deep brain stimulation (DBS) surgery targeting the globus pallidus internus has shown benefit. Physical therapy and speech therapy can also play supportive roles depending on which body areas are affected.
Also known as:
Key symptoms:
Involuntary neck twisting or turning (cervical dystonia)Abnormal head postureNeck pain and stiffnessStrained or breathy voice (laryngeal dystonia)Difficulty speaking clearlyInvoluntary eye blinking or squeezing (blepharospasm)Facial muscle spasmsWriter's cramp or hand cramping during tasksMuscle tightness in the affected areaTremor in the head or handsDifficulty swallowing in some casesSymptoms that worsen with stress or fatigueGradual spread of dystonia to nearby body regions
Clinical phenotype terms (7)— hover any for plain English
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for Autosomal dominant focal dystonia, DYT25 type.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Autosomal dominant focal dystonia, DYT25 type at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Autosomal dominant focal dystonia, DYT25 type.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Autosomal dominant focal dystonia, DYT25 type.
Community
No community posts yet. Be the first to share your experience with Autosomal dominant focal dystonia, DYT25 type.
Start the conversation →Latest news about Autosomal dominant focal dystonia, DYT25 type
No recent news articles for Autosomal dominant focal dystonia, DYT25 type.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Which specific muscles are affected by my dystonia, and is it likely to spread to other areas?,Would botulinum toxin injections be a good first treatment for me, and how often would I need them?,Should I have genetic testing for the GNAL gene, and should my family members be tested too?,Am I a candidate for deep brain stimulation if other treatments don't work well enough?,What oral medications might help, and what side effects should I watch for?,Are there physical therapy exercises or techniques that can help manage my symptoms?,How can I manage the emotional and psychological impact of living with dystonia?
Common questions about Autosomal dominant focal dystonia, DYT25 type
What is Autosomal dominant focal dystonia, DYT25 type?
Autosomal dominant focal dystonia, DYT25 type (also called GNAL-related dystonia or DYT-GNAL) is a rare movement disorder caused by changes in the GNAL gene. Dystonia means that muscles contract involuntarily, causing twisting or repetitive movements and abnormal postures that a person cannot control. In DYT25, the dystonia typically starts in one part of the body — most often the neck (called cervical dystonia or torticollis), the face, or the vocal cords (laryngeal dystonia). Over time, it may spread to involve nearby body regions, but it usually does not become generalized to the whole body
How is Autosomal dominant focal dystonia, DYT25 type inherited?
Autosomal dominant focal dystonia, DYT25 type follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Autosomal dominant focal dystonia, DYT25 type typically begin?
Typical onset of Autosomal dominant focal dystonia, DYT25 type is adult. Age of onset can vary across affected individuals.